Palbociclib
Generic Details
Generic Name
Palbociclib
Other Names
- Ibrance
Drug Class
- CDK4/6 Inhibitor
Chemical Formula
C24H29N7O2
Molecular Weight
447.54 g/mol
Mechanism of Action
- Inhibits cyclin-dependent kinases 4 and 6 (CDK4/6) leading to cell cycle arrest and inhibition of tumor cell proliferation
Indications
- Breast Cancer
Common Dosage Forms
- Capsule
Typical Dosage
- 125 mg daily for 21 days followed by 7 days off treatment cycle
Pediatric Dosage
- Not established
Geriatric Dosage
- Dose adjustment may be needed based on individual patient factors
Side Effects
- Neutropenia
- Fatigue
- Nausea
- Alopecia
- Stomatitis
Contraindications
- Severe hepatic impairment
- Known hypersensitivity to palbociclib or any of its components
Pregnancy Category
- D
Lactation Safety
- May harm the baby, avoid breastfeeding
Drug Interactions
- Strong CYP3A inhibitors/inducers
- Avoid concomitant use with strong/ moderate CYP3A inhibitors
- Consider dose reduction with strong CYP3A inducers
Overdose Symptoms
- Increased toxicity
Antidote for Overdose
- No specific antidote, manage with supportive care
Storage Conditions
- Store at room temperature away from light and moisture
Pharmacokinetics
- Absorption: Well absorbed orally
- Distribution: Highly protein-bound
- Metabolism: Primarily hepatic via CYP3A4
- Excretion: Mainly in feces (74%), with lesser amounts in urine (20%)
Precautions
- Monitor blood counts regularly during treatment
- Monitor liver function tests
- Cardiac monitoring may be required in patients with pre-existing heart conditions
Warnings
- May cause fetal harm if used during pregnancy
- Potential for neutropenia and infections
Others
- Dosage adjustments may be required based on toxicity levels and blood count results